Author/Authors :
Dehghani Fard, Ali tarbiat modares university - Faculty of Medical Sciences - Department of Hematology, تهران, ايران , Kaviani, Saeid tarbiat modares university - Faculty of Medical Sciences - Department of Hematology and Blood Banking, تهران, ايران , Saki, Najmaldin ahvaz jundishapur university of medical sciences - Research Center of Thalassemia Hemoglobinopathy, اهواز, ايران , Mortaz, Esmaeil Utrecht University - Faculty of Sciences, Utrecht Institute for Pharmaceutical Sciences - Division of Pharmacology and Pathophysiology, Netherlands
Abstract :
Beta-thalassemia is considered as genetic disorder characterized by insufficiency or absence of β-globin gene expression with accumulation of α-globin chains in erythroid precursor cells resulting in ineffective erythropoiesis (1, 2). Recently, attempt for augmentation of fetal hemoglobin (HbF) production has been established as a novel therapeutic strategy in blood transfusion independent beta-thalassemia.
